Verastem licenses GenFleet's KRAS inhibitor

14 January 2025

Verastem Oncology (Nasdaq: VSTM) has exercised its option to license certain rights to the cancer candidate VS-7375 from GenFleet Therapeutics.

The decision builds on early clinical data from a Phase I trial, conducted in China, showing promising safety and efficacy in patients with advanced cancers.

The trial, involving 26 patients, reported both confirmed and unconfirmed partial responses, with significant results in pancreatic and non-small cell lung cancer cases. No dose-limiting toxicities were observed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical